PDCD1 and non-small cell lung carcinoma: Both the Food and Drug Administration (FDA) and the National Medical Products Administration (NMPA) of China have approved multiple indications for ICI in clinical practice of NSCLC, including PD-1 inhibitors, PD-L1 inhibitors, and CTLA-4 inhibitors.